Device Trial Radar · NCT07714876
Evaluation of the Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2029
Study completion Dec 2031
Sponsor
- Lead sponsor
- Kardium Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 20, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the long-term safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal atrial fibrillation.
Conditions
- Paroxysmal Atrial Fibrillation
Interventions
Globe Pulsed Field SystemDevice
Ablation and atrial mapping with the Globe Pulsed Field System
Primary outcomes
What the sponsor says the trial is designed to measure.
- 12-month Treatment Success RateTime frame: 12 months
- Primary Safety Event RateTime frame: 7 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Arrhythmia Research Group
Jonesboro, Arkansas
Overlake Hospital
Bellevue, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.